Expert perspectives with Michele Baccarani, MD, interviewed by Jorge Cortes, MD.

This independent medical education activity features an expert interview with Michele Baccarani, MD, and Jorge Cortes, MD, focusing on important data from a recent publication that reported the 24-month follow-up results of a randomized, phase II study investigating nilotinib for treating patients with chronic myelogenous leukemia (CML) in chronic phase following imatinib resistance or intolerance (Kantarjian HM, et al. Blood. 2010 Nov 22. [Epub ahead of print]).

Dr Baccarani briefly discusses the rationale for the phase II clinical trial reported in this publication, as well as the efficacy, tolerability, and safety of nilotinib in patients with chronic-phase CML intolerant or resistant to imatinib.